BIOKIN's SI-B036 Bispecific Antibody Injection Receives Clinical Trial Approval for Advanced Solid Tumors

Stock News05-14

Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SH) has announced that it recently received the official "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA). The company's self-developed innovative biologic drug, the SI-B036 bispecific antibody injection, has obtained approval for clinical trials, permitting the initiation of monotherapy trials in patients with advanced solid tumors.

It is reported that the SI-B036 bispecific antibody injection is one of the products from the company's self-developed, globally leading Specificity-Enhanced Bispecific Antibody (SEBA) platform. SEBA molecules not only enhance targeting and anti-tumor activity but also minimize off-target effects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195337274?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 17:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195337274","market":"fut","top_or_hot":-1,"title":"BIOKIN's SI-B036 Bispecific Antibody Injection Receives Clinical Trial Approval for Advanced Solid Tumors","media":"Stock News","content":"<p>Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SH) has announced that it recently received the official \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration (NMPA). The company's self-developed innovative biologic drug, the SI-B036 bispecific antibody injection, has obtained approval for clinical trials, permitting the initiation of monotherapy trials in patients with advanced solid tumors.</p>\n<p>It is reported that the SI-B036 bispecific antibody injection is one of the products from the company's self-developed, globally leading Specificity-Enhanced Bispecific Antibody (SEBA) platform. SEBA molecules not only enhance targeting and anti-tumor activity but also minimize off-target effects.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOKIN's SI-B036 Bispecific Antibody Injection Receives Clinical Trial Approval for Advanced Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOKIN's SI-B036 Bispecific Antibody Injection Receives Clinical Trial Approval for Advanced Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-14 17:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SH) has announced that it recently received the official \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration (NMPA). The company's self-developed innovative biologic drug, the SI-B036 bispecific antibody injection, has obtained approval for clinical trials, permitting the initiation of monotherapy trials in patients with advanced solid tumors.</p>\n<p>It is reported that the SI-B036 bispecific antibody injection is one of the products from the company's self-developed, globally leading Specificity-Enhanced Bispecific Antibody (SEBA) platform. SEBA molecules not only enhance targeting and anti-tumor activity but also minimize off-target effects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SI","symbol_name":"Shoulder Innovations, Inc.","start_time":0,"source_url":"","article_id":"1195337274","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195337274","pubTimestamp":1778750903,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SH) has announced that it recently received the official \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration (NMPA)....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"91194":"临工重机股份有限公司（临时代码）","688506":"百利天恒","SI":"Shoulder Innovations, Inc.","BK4082":"医疗保健设备","02615":"百利天恒","BK0239":"医药制造","BK4211":"区域性银行"},"translate_title":"BIOKIN公司SI-B036双特异性抗体注射液获晚期实体瘤临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91194":1,"688506":1,"SI":1,"02615":1},"content_text":"Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SH) has announced that it recently received the official \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration (NMPA). The company's self-developed innovative biologic drug, the SI-B036 bispecific antibody injection, has obtained approval for clinical trials, permitting the initiation of monotherapy trials in patients with advanced solid tumors.\nIt is reported that the SI-B036 bispecific antibody injection is one of the products from the company's self-developed, globally leading Specificity-Enhanced Bispecific Antibody (SEBA) platform. SEBA molecules not only enhance targeting and anti-tumor activity but also minimize off-target effects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195337274","isCrawlerRequest":true}